Drug intelligence / Profile preview

ISA104

Development stage: Phase 2
Lead developer: ISA Pharmaceuticals
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

ISA104 is an investigational therapeutic **synthetic long peptide vaccine** for chronic hepatitis B developed by ISA Therapeutics in collaboration with Erasmus MC. It comprises 12 synthetic long peptides derived from conserved regions of hepatitis B virus antigens and ISA's AMPLIVANT adjuvant technology. The vaccine is intended to induce a strong, HBV-specific cellular immune response, including vaccine-directed T-cell responses, with the goal of achieving a functional cure of chronic hepatitis B. It is being evaluated in the randomized HEB-PEP dose-escalation study. ([onderzoekmetmensen.nl](https://onderzoekmetmensen.nl/en/trial/51362))

Targets

HBV antigens (Hepatitis B virus antigens)

Beyond the preview

Go deeper on ISA104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISA104.

Explore the full profile